UNLABELLED
The overexpression of cell surface receptors on cancer cells is a potential target for the design of receptor-binding radiopharmaceuticals for tumor imaging. The sensitivity of these agents depends on the interaction in vivo of factors such as the level and heterogeneity of receptor expression, the proportion of targeted cells, the tumor/ nontarget (T/NT) ratio and attenuation by overlying normal tissue. The relative importance of a single factor or combination of factors is unknown. Our objective was to evaluate, under controlled experimental conditions, the effect of these factors on the sensitivity for imaging breast cancer with a new receptor-binding radiopharmaceutical: human epidermal growth factor (HEGF)51 labeled with 111In.
METHODS
MDA-MB-468, S1 or MCF-7 breast cancer cells expressing 1.3 x 10(6), 3.3 x 10(4) and 1.5 x 10(4) epidermal growth factor receptors (EGFR)/cell were targeted in vitro with 111In-HEGF51. Phantoms were constructed with an internal well to simulate a lesion and surrounded by an outer well to simulate normal tissue. The effect of the level of receptor expression was studied with phantoms containing targeted MDA-MB-468, S1 or MCF-7 cells. The effect of the proportion of cells targeted was evaluated using phantoms containing mixed targeted or nontargeted MDA-MB-468 cells. Receptor heterogeneity was studied using phantoms containing mixed MDA-MB-468 and S1 cells. The T/NT ratio was evaluated by varying the concentration of radioactivity in the outer well and tissue attenuation was simulated by overlaying the phantoms with water. Phantoms were imaged using a gamma camera fitted with a medium-energy collimator interfaced to a computer.
RESULTS
The sensitivity for detection of a lesion was directly proportional to the level of receptor expression or to the proportion of cells targeted and inversely proportional to the level of receptor heterogeneity. A T/NT ratio > or = 2:1 was required for detection. Under ideal conditions with a single factor varied, as few as 5 x 10(4) to 10(5) MDA-MB-468 cells with a high level of EGFR expression or 2.5 x 10(5) to 10(6) S1 or MCF-7 cells with a low level of EGFR expression were detected. When the receptor heterogeneity, the proportion of targeted cells and tissue attenuation were varied in combination with a T/NT ratio of 3:1, the sensitivity for detection approached that observed clinically with receptor-binding radiopharmaceuticals (10(7) cells).
CONCLUSION
Our results suggest that combinations of four factors may account for the relatively low sensitivity for tumor imaging observed clinically with receptor-binding radiopharmaceuticals and, in particular, strategies aimed at minimizing the effects of receptor heterogeneity; a low proportion of cells targeted and tissue attenuation would improve the detection of small lesions.
[1]
A. Harris,et al.
Quantitative assays of epidermal growth factor receptor in human breast cancer: Cut‐off points of clinical relevance
,
1988,
International journal of cancer.
[2]
K. D. Hardman,et al.
In vivo tumor targeting of a recombinant single-chain antigen-binding protein.
,
1990,
Journal of the National Cancer Institute.
[3]
B F Hutton,et al.
A scanning line source for simultaneous emission and transmission measurements in SPECT.
,
1993,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4]
T. Iga,et al.
Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats.
,
1989,
Biochemical pharmacology.
[5]
D. Carlo,et al.
Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018.
,
1987,
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6]
M. Mottolese,et al.
Somatostatin receptor imaging in CNS tumours using 111In‐octreotide
,
1995,
Nuclear medicine communications.
[7]
E. Krenning,et al.
Somatostatin and the concept of peptide receptor scintigraphy in oncology.
,
1994,
Seminars in oncology.
[8]
P. Sharp,et al.
The influence of size and radiopharmaceutical concentration ratio on the detection of abnormalities in clinical radionuclide imaging.
,
1978,
The British journal of radiology.
[9]
J. Foekens,et al.
Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: Relationship to egf receptors
,
1990,
International journal of cancer.
[10]
S. Elsea,et al.
Pharmacokinetic evaluation of two human epidermal growth factors (hEGF51 and hEGF53) in rats.
,
1992,
Drug metabolism and disposition: the biological fate of chemicals.
[11]
R. Mariani-Costantini,et al.
Regional heterogeneity and complementation in the expression of the tumor-associated glycoprotein 72 epitopes in colorectal cancer.
,
1991,
Cancer research.
[12]
J. Wittliff,et al.
Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels.
,
1984,
Cancer research.
[13]
A. Hubbard,et al.
Receptor-mediated endocytosis of epidermal growth factor by hepatocytes in the perfused rat liver: ligand and receptor dynamics
,
1984,
The Journal of cell biology.
[14]
L. Skoog,et al.
Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma.
,
1988,
Anticancer research.